52
Participants
Start Date
May 31, 2014
Primary Completion Date
July 31, 2017
Study Completion Date
May 31, 2018
Rituximab
Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
Placebo
The placebo group will receive a vehicle control infusion
Columbia University Medical Center, New York
Weill Cornell Medical Center, New York
Montefiore Medical Center, The Bronx
SUNY Downstate Medical Center, Brooklyn
SUNY Stony Brook, Stony Brook
SUNY Buffalo, Buffalo
University of Rochester, Rochester
University of Pittsburgh, Pittsburgh
University of Virginia, Charlottesville
Emory University, Atlanta
University of Miami School of Medicine, Miami
University of Alabama at Birmingham, Birmingham
Ohio State University, Columbus
University of Cincinnati, Cincinnati
Northwestern University, Evanston
Washington University, St Louis
University of Kansas Medical Center, Kansas City
University of Texas Southwestern Medical Center, Dallas
University of Colorado - Denver, Denver
University of Utah, Salt Lake City
University of California - Los Angeles, Los Angeles
University of California - Davis, Davis
Oregon Health and Science University, Portland
Swedish Medical Center, Seattle
Yale School of Medicine, Department of Neurology, New Haven
Brigham & Women's Hospital, Boston
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Yale University
OTHER